|
Reference
|
Intervention treatment |
No. of patients
randomized
|
Comparison treatment
|
No. of patients
randomized
|
Followup
time
|
|
Klotz (13)
(CS21,global)
|
Degarelix: 240mg initial dose
80mg Monthly
or
Degarelix: 240mgintial dose
16mg monthly
|
Number: 210
Number: 206
|
Leuprorelin: 7.5mg
Monthly
with or without
bicalutamide
|
Number: 204
(11 % received
flare protection)
|
12
months
|
|
Anderson (14)
(CS28,United
Kingdom)
|
Degarelix: 240mg initial dose
80mg Monthly
|
Number: 29
|
Goserelin 3.6mg on
days 3, 31, and 59
and bicalutamide
on days 0-17
|
Number: 13 (all
cases received
flare protection )
|
3 months
|
|
Mason (15)
(CS30,USA&W
estern Europe)
|
Degarelix: 240mg initial dose
80mg Monthly
|
Number: 181
|
Goserelin 3.6mg on
days 3, 31, and 59
andbicalutamide
50mg daily on days
0-16
|
Number: 65 (all
cases received
flare protection)
|
3 months
|
|
Axcrona (16)
(CS31,Scandina
via)
|
Degarelix: 240mg initial dose
80mg Monthly
|
Number: 84
|
Goserelin 3.6mg on
day 0, 28, and 56 +
bicalutamide 50mg
daily on days 0-28
|
Number: 98 (all
cases received
flare protection)
|
3 months
|
|
Tombal (11)
(global)
|
Degarelix: 240mg initial dose
80mg Monthly
or
Degarelix: 240mg intial dose
16mg monthly
|
Number: 210
Number: 206
|
Leuprorelin: 7.5mg
Monthly
with or without
bicalutamide
|
Number: 204
(11 % received
flare protection)
|
12
months
|
|
Iversen (12)
(global)
|
Degarelix: 240mg initial dose
80mg Monthly
or
Degarelix: 240mg intial dose
16mg monthly
|
Number: 210
Number: 206
|
Leuprorelin: 7.5mg
Monthly
with or without
bicalutamide
Number:204
(11 % received
flare protection)
|
12
months
|
